Sentences with phrase «results from phase»

Additional phases will commence as results from phase One dictate.

That calculation is only as good as your results from phase 2 trials.

«The Continual Intercomparison of Radiation Codes: Results from Phase I.» Journal of Geophysical Research: Atmospheres, 117 (D6), 10.1029 / 2011jd016821.

IGNORE THESE FINDINGS AT YOUR PERIL: Project RED Announces Significant Results from Phase III Research

This resource has: a) Ideas for investigating the Phase 10 Data (Ten Investigations using CensusAtSchool Phase 10 Data.doc), b) A spreadsheet containing the counts and percentages of the results from Phase 10 up to February 2011 (CensusAtSchool Phase 10 summary spreadsheet.xls), c) A learners» worksheet to help them plan their investigation (CensusAtSchool Planning Worksheet.doc), d) An instruction sheet to use Pivot Tables in Excel (Pivot Tables in Excel.doc) e) A spreadsheet to be used with the Pivot Tables in Excel worksheet (Pivot Tables in Excel.xls).

Early results from a phase one study to establish the recommended dose of the OTX015 / MK -8628 BET inhibitor in hematologic malignancies reported the drug was tolerated; however, thrombocytopenia was a common toxic effect observed (Amorim et al., 2016).

The first - of - its - kind study found the dual treatments to be safe and elicit a clinical response in patients, according to new results from a phase I trial to be presented at the AACR Annual Meeting 2015 on Sunday, April 19 (Abstract #CT137).

Following positive initial results from Phase I safety trials evaluating direct administration of VRC01, an HIV - specific antibody that is able to neutralize a broad variety of HIV strains, the National Institute of Allergy and Infectious Diseases (NIAID) is preparing for a series of further studies to see if this broadly neutralizing antibody is effective in preventing transmission of HIV from mothers to their infants, as well as among high - risk adults.

deCODE genetics (Nasdaq: DCGN) today announced positive top - line results from its Phase I multiple dose clinical trial of DG051, which the company is developing for the prevention of heart attack.

February 21, 2006 deCODE genetics (Nasdaq: DCGN) today announced top - line results from Phase I clinical studies of DG041, the company's developmental compound for the treatment of peripheral artery disease (PAD).

Reykjavik, ICELAND, January 9, 2008 — deCODE genetics (Nasdaq: DCGN) today announced positive topline results from its Phase IIa clinical trial for DG051, the company's leukotriene A4 hydrolase inhibitor being developed for the prevention of heart attack.

The drug was approved based on efficacy and safety results from a phase III trial presented earlier this year at the 2015 American Society of Clinical Oncology Annual Meeting.

Results from Phase I and Phase II clinical trials were encouraging, with significant vision improvements reported for some patients.

Reykjavik, ICELAND, October 19, 2004 — deCODE genetics (Nasdaq: DCGN) today announced the principal results from its Phase IIa information - rich clinical trial ™ of DG031, the company's developmental compound which is being studied for the prevention of heart attack.

Robert Motzer, M.D., of Memorial Sloan Kettering Cancer Center, presented results from a phase 2 trial of nivolumab in renal cell carcinoma (RCC), commonly known as kidney cancer.

Clinical Breast Cancer 2013, Final Results from Phase II Trial of Neoadjuvant Docetaxel and Capecitabine Given Sequentially or Concurrently for HER2 - Negative Breast Cancers

5: Jankovic J, Goodman I, Safirstein B, Schenk D, Kinney GG, Koller M, Ness DK, Griffith SG, Grundman M, Soto J, Ostrowitzki S, Boess FG, Martin - Facklam M, Quinn JF, Isaacson SH, Jennings D, Omidvar O, Ellenbogen A. Results from a Phase 1b multiple ascending - dose study of PRX002, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson's disease.

Results from a phase 1 study of nusinersen (ISIS - SMNRx) in children with spinal muscular atrophy.

5a: Jankovic J, Goodman I, Safirstein B, Schenk D, Kinney G, Koller M, Ness DK, Griffith S, Grundman M, Soto J, Ostrowitzki S, Boess F, Martin - Facklam M, Quinn J, Isaacson S, Jennings D, Omidvar O, Ellenbogen A. Results From a Phase 1b multiple ascending - dose study of PRX002, an anti — alpha - synuclein monoclonal antibody, in patients with Parkinson's disease [abstract].

An anti-PD-1 antibody developed by Bristol - Myers Squibb generates excitement with results from a phase I trial showing that, among 236 patients with various types of cancer, the treatment shrank tumors in 28 percent of melanoma patients, 30 percent of patients with kidney cancer, and 18 percent of patients with advanced non-small cell lung cancer.

CRI: The results from your phase I study that were published last year were impressive and got a lot of media attention.

Early results from a phase I, first in - human study indicate that a potential new class of drugs, RNA interference (RNAi) drugs, can be safely administered in humans, according to a researcher who presented data on the safety and preliminary efficacy of TKM - 080301 at the AACR Annual Meeting 2013, held in Washington, D.C., April 6 - 10.

The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also showed promise in previously treated pancreatic cancer patients with the mutation, according to results from a phase II clinical study.

Results from a phase III trial with another antibody that targets β amyloid — solanezumab, developed by Eli Lilly — should be announced later this year.

Afferent Pharmaceuticals today announced publication of results from a Phase 2 clinical trial demonstrating that the company's novel drug candidate, AF - 219, reduced daytime cough frequency by 75 % compared to placebo in patients with treatment - refractory chronic cough.

Last week, at the Psychedelic Science 2017 conference in Oakland, California, researchers presented unpublished results from phase II trials involving a total of 107 people diagnosed with PTSD.

The first - of - its - kind study found the dual treatments to be safe and elicit a clinical response in patients, according to new results from a phase I trial to be presented at the AACR Annual Meeting 2015 on April 19.

An affordable hepatitis C combination treatment including the new drug candidate ravidasvir has been shown to be safe and effective, with extremely high cure rates for patients, including hard - to - treat cases, according to interim results from the Phase II / III STORM - C - 1 trial presented by the non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) at the International Liver Conference in Paris.

He says results from phase II and III trials on these new therapies designed to stall the disease are slated to come out within the year.

We look forward to the results from the phase III trial with interest.»

«Based on the results from these Phase 3 studies, the combination of bictegravir and FTC / TAF could represent an important advance in triple - therapy treatment for a broad range of HIV patients, and we look forward to submitting regulatory applications in the U.S. and EU this year.»

Detailed 48 - week results from a Phase 3 study evaluating the efficacy and safety of switching from a regimen containing abacavir, dolutegravir and lamivudine (600 / 50/300 mg)(ABC / DTG / 3TC) to Biktarvy, a once - daily single tablet regimen, in virologically suppressed adults with HIV.

The Finnish drug maker on Sunday presented results from phase I trial of a prostate cancer treatment, saying according the data it «has been well tolerated, with no significant treatment - related adverse events.»

BIIB098: MRI and relapse results from the phase 3 EVOLVE - MS - 1 study in patients with relapsing and remitting multiple sclerosis were presented at the 70th annual meeting of the American Academy of Neurology (AAN).

These statistically significant and clinically meaningful improvements in overall response and survival rates resulted from a phase Ib / II clinical study performed at the HonorHealth Research Institute, a partnership of HonorHealth and TGen.

Not exact matches

Alexion Reports First Quarter 2018 Results and Positive Topline Data from ALXN1210 Phase 3 PNH Switch Study

Among the factors that could cause actual results to differ materially are the following: (1) worldwide economic, political, and capital markets conditions and other factors beyond the Company's control, including natural and other disasters or climate change affecting the operations of the Company or its customers and suppliers; (2) the Company's credit ratings and its cost of capital; (3) competitive conditions and customer preferences; (4) foreign currency exchange rates and fluctuations in those rates; (5) the timing and market acceptance of new product offerings; (6) the availability and cost of purchased components, compounds, raw materials and energy (including oil and natural gas and their derivatives) due to shortages, increased demand or supply interruptions (including those caused by natural and other disasters and other events); (7) the impact of acquisitions, strategic alliances, divestitures, and other unusual events resulting from portfolio management actions and other evolving business strategies, and possible organizational restructuring; (8) generating fewer productivity improvements than estimated; (9) unanticipated problems or delays with the phased implementation of a global enterprise resource planning (ERP) system, or security breaches and other disruptions to the Company's information technology infrastructure; (10) financial market risks that may affect the Company's funding obligations under defined benefit pension and postretirement plans; and (11) legal proceedings, including significant developments that could occur in the legal and regulatory proceedings described in the Company's Annual Report on Form 10 - K for the year ended Dec. 31, 2017, and any subsequent quarterly reports on Form 10 - Q (the «Reports»).

While young / first - steps content marketers can learn many things from their more mature peers, one of the most striking — and encouraging — observations about those in the early phase is that 71 % agree that their organization is focused more on building long - term relationships than on getting quick results from content marketing.

Instead of working on the demand side, attention has turned to stimulating business through tax cuts, entrepreneurship and innovation while phasing out excess capacity resulting from the previous stimulus.

Interim results showed that a majority of the 22 patients in the two Phase 1/2 studies followed for two years or longer remained free from transfusions.

The Study And The Results The full data from the Phase III study,...

But the numbers are equally fun while being in the building phase, and I get a lot of motivation from tracking my own results and seeing progress made by others.

George Budwell (Trevena): The clinical - stage biotech Trevena is set to release top - line results from two phase 3 studies (APOLLO - 1 and APOLLO - 2) for its lead drug candidate, oliceridine, in the first quarter of 2017.

For each phase there corresponds a particular modification of the subjective aim, the «subjective end» of that phase.30 The modification results from the way antecedent feelings influence the subjective end, and that subjective end in turn influences successor feelings.

We can understand Russell's later cautious advocacy of an explicitly metaphysical position as in part resulting from a consistent and continued commitment to, and application of, this method of logical construction, together with a dispassionate exploration of its full implications, rather than writing off this later phase as entirely distinct and grossly inconsistent with the earlier phases of Russell's career.

But the Darwinian stage showed that the cosmic process extends from sidereal space to life on earth; with the result that, in the present phase, Man finds himself overtaken and borne on the whirlwind which his own science has discovered and, as it were, unloosed.

Those, however, who hope for unity through culture regard this diversity between cultures as a transitional phase preceding the development of a world culture which will result from cross-fertilization between national or racial cultures.

Accordingly, in the integrative phase of the occasion it is merely reunited with the physical feeling from which it was derived; the resulting feeling is called a «physical purpose.»

Sonic's new policy will result in the company phasing - in the use of cage - free eggs as well as pork from facilities that do not confine breeding pigs in gestation crates.

In this phase it's important to assess the demands of your athletes» sport (movement patterns, speed, power and fatigue) when it comes to training the qualities that will result in optimal performance transfer from the gym.